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Naturally occurring antibody responses to Plasmodium falciparum rhoptry-associated proteins 1 and 2
(RAP-1 and RAP-2) were measured with recombinant and parasite-derived forms of the antigens. For com-
parative purposes, responses to multiple forms of three other malarial antigens were also examined. The sera
of 100 Papua New Guineans were screened for antibodies. Eighty-six and 82% of individuals over 30 years of
age had antibodies that recognized parasite-derived RAP-1 and RAP-2, respectively. Importantly, we found that
recombinant and native antigens share linear epitopes seen by the human immune system; thus, the recom-
binant proteins may be adequate human immunogens. However, antibodies affinity purified on recombinant
RAP-1 reacted with other antigens in addition to parasite-derived RAP-1. Thus, the antigenicity of RAP-1 may
have been overestimated previously. The recognition of RAP-1 and RAP-2 correlated with age and with the
recognition of recombinant forms of the ring-infected erythrocyte surface antigen, merozoite surface protein 1,
and merozoite surface antigen 2 (MSA2) antigens. Antibodies to these antigens appear to be generated in
response to the total exposure to malaria of the host. Antibodies to conserved regions of MSA2 had stronger
correlations with both age and the recognition of other antigens than did the full-length recombinant MSA2
molecule. In contrast to results with the other antigens, there was no significant difference in the ages of
individuals with a certain antibody titer to the full-length recombinant or parasite-derived MSA2 molecule, but
antibodies to these two antigens did correlate with parasitemia. For all antigens tested, antibody levels after
two infections can approach the peak levels of antibodies obtained in immune individuals.
Several proteins have been identified from the rhoptry or-
ganelles of Plasmodium falciparum. These include two protein
complexes, a high-molecular-mass complex, RhopH (contain-
ing 140-, 130-, and 110-kDa proteins [4, 10]), and a low-mo-
lecular-mass complex, QF3 (5, 33). The second complex con-
sists of two proteins, namely, rhoptry-associated proteins 1 and
2 (RAP-1 and RAP-2, respectively) (27).
RAP-1 and RAP-2 are considered candidate antigens for a
subunit malaria vaccine. Monoclonal antibodies (MoAbs) di-
rected against RAP-1 and RAP-2 can give substantial inhibi-
tion of parasite invasion in vitro (8, 15, 20, 26, 33). Three of
four Saimiri scureus monkeys immunized with a mixture of
RAP-1 and RAP-2 isolated from the K1 line of P. falciparum
were protected from a subsequent challenge with the Uganda
Palo Alto line (28), with substantially lower peak levels of
parasitemia and lower initial rates of growth than those of the
control animals. Protection from P. falciparum challenge was
also obtained in Saimiri monkeys immunized with a mixture of
parasite aldolase, serine protease, and QF3 (25).
The genes coding for RAP-1 and RAP-2 have been cloned
(29, 31), revealing no homology to other known genes. Further,
RAP-1 and RAP-2 show minimal sequence polymorphisms
between P. falciparum isolates (17, 19, 29, 31, 38). Thus, the
antigenic diversity that presents a major difficulty for other
malaria vaccine candidates may not be important for RAP-1
and RAP-2.
Recombinant forms of both proteins have been produced
(rRAP-1 and rRAP-2) and found to be immunogenic in animal
models (37, 38). Immunization of mice and rabbits with dena-
tured rRAP-1 and rRAP-2 produced polyclonal antibodies
which recognized linear epitopes in the recombinant proteins
and gave partial inhibition of parasite invasion in vitro. To
determine if human antibodies resulting from a natural infec-
tion with P. falciparum also recognize linear epitopes within
the recombinant proteins, this study assessed the antigenicities
of these recombinant forms of RAP-1 and -2.
First, we examined the humoral responses to rRAP-1 and
rRAP-2 in the sera of a population from an area of Papua New
Guinea (PNG) where malaria is endemic. These responses
were then compared to responses against parasite-derived
forms of RAP-1 and -2 (herein designated P. falciparum
RAP-1 and -2). Studies have been performed with recombi-
nant forms of RAP-1 (18, 22) but never with parasite-derived
forms or with either type of RAP-2. The two above-described
studies found that following natural infection with P. falcipa-
rum, 29 of 30 immune and semi-immune donors had rRAP-1-
reactive immunoglobulin G (IgG) with higher reactivity to the
N-terminal 294 amino acids than to the C-terminal 466 amino
acids. This reactivity was not directed against the serine repeat
region (18). At least one T-cell epitope in the N-terminal 294
amino acids of rRAP-1 was recognized by 14 of 15 malaria-
immune human donors (22).
Second, we established how quickly an antirhoptry protein
response arises by examining the responses to both the recom-
binant and parasite-derived RAP-1 and RAP-2 proteins in the
sera of volunteers undergoing a single defined P. falciparum
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infection. The boosting effect on titers of antibodies of a sub-
sequent infection was also examined.
Third, we assessed the relative antigenicities of rRAP-1 and
-2 compared with those of other malarial vaccine candidates by
examining the responses of the same PNG sera to three other
malarial proteins. These were recombinant and parasite-de-
rived forms of merozoite surface antigen 2 (MSA2 [36]), re-
combinant forms of merozoite surface protein 1 (MSP1 [16]),
and a recombinant form of ring-infected erythrocyte surface
antigen (RESA [11]). These three antigens are all potential
vaccine candidates, on the basis of in vitro inhibition of eryth-
rocyte invasion by antibodies raised against the molecules and
by protection seen in vivo in primate and mouse models (21).
RESA, MSA2, and MSP1 have been more extensively studied
than RAP-1 and -2, making them ideal for comparative pur-
poses.
MATERIALS AND METHODS
Parasite culture. P. falciparum clone 3D7 from the Netherlands isolate NF54
(44) was cultured in vitro as described previously (43).
PNG serum collection. Sera were collected from 100 individuals; 21 were 0 to
5 years old, 19 were .5 to 10 years old, 19 were .10 to 15 years old, 19 were .15
to 30 years old, and 22 were .30 years old. The collection was from 12 villages
from the Madang province of PNG. P. falciparum is endemic in Madang, with
perennial transmission peaking in the wet season (November to March). Sera
were collected as part of a series of epidemiology studies (6) from June to August
1982 and stored as a reference collection at 270°C. At the time of collection,
thick blood films were prepared, stained with 4% Giemsa stain, and scored for
malaria parasites: a score of 0 indicated a negative test, 1 indicated ,80 para-
sites/mm3, 2 indicated 81 to 200 parasites/mm3, 3 indicated 201 to 600 parasites/
mm3, 4 indicated 601 to 1,400 parasites/mm3, 5 indicated 1,401 to 3,400 parasites/
mm3, 6 indicated 3,401 to 8,000 parasites/mm3, 7 indicated 8,001 to 19,960
parasites/mm3, 8 indicated .19,960 parasites/mm3, and 9 indicated missing data.
Serum samples were kindly supplied by PNG Institute of Medical Research.
Defined P. falciparum infections. Two volunteers, one with no previous ma-
larial exposure and the other with a prior Plasmodium vivax infection, were
infected by Anopheles stephensi (Dutch) mosquitoes carrying sporozoites of P.
falciparum clone 3D7 as part of a project to develop a challenge system for the
testing of malaria vaccines (7). The course of infection was allowed to run for 14
days for the first volunteer and 13 days for the second volunteer (parasite
densities were 200 and 18 parasites per ml of whole blood at treatment, respec-
tively. One unit of whole blood was taken from each volunteer prior to treatment
and cryopreserved. Blood samples were taken daily, and the plasma was used
for this study. One year following the initial sporozoite infection, both vol-
unteers were rechallenged with a blood stage inoculum of 3,000 parasites
prepared from their previous infection, and the infection was allowed to run
for 8 days.
Antigen preparation and control antibodies. P. falciparum RAP-1 and P.
falciparum RAP-2 were affinity purified from Percoll-purified schizonts of in
vitro-cultured P. falciparum clone 3D7 with two MoAbs (7H8/50 for P. falcipa-
rum RAP-1 and 3A9/48 for P. falciparum RAP-2 [5, 33]). Briefly, 6 liters of
synchronous cultures of clone 3D7-parasitized erythrocytes was purified on col-
loidal silica gradients (32), giving 2 ml of 90% 3D7 schizonts. Schizont antigen
was extracted three times with Triton X-100 (5) to give a 30-ml antigen prepa-
ration. P. falciparum RAP-1 and P. falciparum RAP-2 were affinity purified from
this preparation by three passages through an immunoaffinity absorbent solution
prepared by coupling both MoAbs (7H8/50 and 3A9/48) to cyanogen bromide-
activated Sepharose 4B (5). P. falciparum RAP-1 and P. falciparum RAP-2 were
eluted in 0.1 M glycine, pH 2.5, and neutralized by the addition of Tris to 0.3 M.
A final purification step used isotachophoretic nonreducing sodium dodecyl
sulfate (SDS)-electrophoresis to separate the two proteins in the native complex
both from each other and from contaminants (39). After elution from affinity
columns, SDS was added to 1% (wt/vol) and the eluate was dialyzed into 150 mM
Tris–0.01% (wt/vol) SDS (pH 7.5). This material was loaded onto a 3- by 500-mm
4% polyacrylamide column prepared in 150 mM Tris (pH 7.5). The trailing
buffer was 127 mM Tris–90 mM glycine–0.01% (wt/vol) SDS, and the current flux
was kept to 0.03 mA/mm2 (39). This ensured that although they were denatured,
P. falciparum RAP-1 and P. falciparum RAP-2 were not reduced.
rRAP-1 and rRAP-2. Purified rRAP-1 and rRAP-2 were identical to material
used in animal immunogenicity studies (37, 38). Both proteins are expressed
from Escherichia coli expression systems. rRAP-2 codes for the entire mature
sequence of the FCQ27/PNG allele of RAP-2, while rRAP-1 codes for a short-
ened form of the mature sequence of the K1 allele of RAP-1, amino acids 23 to
608.
MSP1. Recombinant antigen MSP1 (rMSP1) (or antigen 190L [14]) contains
amino acids 147 to 321 of the K1 allele of MSP1, equivalent to blocks 3 (con-
served) and 4 (variant) (41). The recombinant protein was expressed in E. coli
with two additional histidines on the N terminus and four additional histidines on
the C terminus and linked to a 17-residue sequence encoding the universal T-cell
epitope from the CS protein to give a molecular mass of 25,209 Da (14). A
second recombinant form of antigen MSA1, expressed from yeast, yMSP119 (23),
was supplied by David Kaslow (National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, Md.) and codes for the C-
terminal 19-kDa fragment of MSP1 from the K1 allele. This molecule is correctly
folded to duplicate the epidermal growth factor-like domains in native MSP1 as
judged by the binding of conformationally dependent MoAbs. yMSP119 was
identified by the MSP1 conformationally dependent MoAb 4H9/19 (9).
MSA2. Recombinant antigen MSA2 (rMSA2) (or antigen 1624 or protein Ro
46-2924 [1, 40]) is an E. coli-expressed recombinant protein containing nearly the
entire length of the mature version of the 3D7 allele of MSA2, with a molecular
mass of 25,606 Da. Parasite-derived MSA2 (P. falciparum MSA2) was not affinity
purified, but comparison of the binding of anti-rMSA2 sera to P. falciparum
schizont extracts of the 3D7 clone as analyzed by SDS-polyacrylamide gel elec-
trophoresis (PAGE) and immunoblotting clearly identified the location of P.
falciparum MSA2 (hence of the 3D7 allele) as one of the dominant bands
recognized by human antisera to malaria. Recombinant antigen NC (rNC) also
corresponds to clone 3D7’s MSA2 but encodes only the N- and C-terminal
portions of MSA2 totally conserved across alleles (amino acids 21 to 43 and 168
to 224 of the 3D7 sequence [26a]).
RESA. Recombinant antigen RESA (rRESA) (or antigen 1505H) is an 89-kDa
E. coli recombinant form of RESA and corresponds to the C-terminal 771
residues of the RESA polypeptide from the FCQ27/PNG strain of P. falciparum,
with a molecular mass of 89,357 Da (2). Mouse sera raised against rMSP1,
rMSA2, and rRESA were supplied by David Pye (CSL Ltd., Melbourne, Aus-
tralia) and used as positive controls.
Schizont antigen. P. falciparum clone 3D7 refers to the recognition of total
parasite schizont antigen from the 3D7 clone grown in vitro and extracted into
Triton X-100 (5, 33).
Supplier. Antigens rMSA2, rRESA, and rMSP1 were all supplied by Sara-
mane Pty Ltd. (Melbourne, Australia) and were identical to material used in
several phase I human immunogenicity trials (30a, 40).
Immunochemical techniques. (i) SDS-PAGE. SDS-PAGE and immunoblot-
ting procedures were as described previously (12), with PNG serum at a dilution
of 1/400 in phosphate-buffered saline (PBS), anti-human IgG (gamma chain-
specific) secondary antibodies conjugated to alkaline phosphatase, and nitroblue
tetrazolium-BCIP (5-bromo-4-chloro-3-indolylphosphate toluidinium) used in
the development reaction. Immunoblot strips incubated with individual serum
samples contained the following amounts of antigen: 6.3 ng of rRAP-1; 37.5 ng
of rRAP-2; 25 ng of rMSP1, rRESA, and rMSA2; 50 ng of P. falciparum RAP-1,
P. falciparum RAP-2, yMSP119, and rNC; and 0.75 ml of P. falciparum clone 3D7
extract. After development, immunoblots were scored by eye in the range of 0 to
6 for signal strength to give immunoblot antibody units.
(ii) ELISAs. Enzyme-linked immunosorbant assays (ELISAs) were performed
with Nunc Immunoplates (Maxisorp) coated with 50 ng of rMSP1, rRESA, or
rMSA2 per well; 100 ng of rRAP-2 per well; 25 ng of rRAP-1, P. falciparum
RAP-1, or P. falciparum RAP-2 per well; and 50 ml of a 1/200 dilution of P.
falciparum 3D7 extract in PBS per well. Primary antibodies in a 1/100 or 1/400
dilution were plated out in triplicate (with a control series for every plate).
Anti-human IgG (gamma chain-specific) secondary antibody conjugated to
horseradish peroxidase with o-phenylenediamine dihydrochloride as a substrate
was used for detection, and absorbances at 450 nm were read. A regression line
was fitted to the control series for each antigen, and the average of the triplicate
readings of optical density at 450 nm (OD450) for each serum sample was
converted to antibody units based on the standard curve. When end point titers
in sera were required, serial dilutions were used and end points were calculated
as the inverse of the serum dilution which gave an OD450 of 0.1 above back-
ground. Positive control mouse sera were used in both immunoblots and
ELISAs. This was especially important in immunoblots, where control strips
were run every third strip to identify the antigens being recognized (e.g., P.
falciparum MSA2).
Controls. For both immunoblot analyses and ELISAs, background levels of
antibody were estimated with the sera of 26 nonexposed individuals from Bris-
bane, Australia. Positive signals for the PNG sera for immunoblot analyses and
ELISAs were then considered those greater than the mean plus 2 standard
deviations of quantitations of signals in the Brisbane sera.
Affinity purification of antibody. Recombinant antigens rRESA and rRAP-1
were reacted separately with CNBr-Sepharose 4B (30 or 50 mg per ml of resin)
for 16 h at 4°C in 0.2 M NaHCO3–0.5 M NaCl, pH 8.8. Columns were blocked
for 4 h at 4°C with 0.2 M glycine (pH 8.0) and then washed with 10 column
volumes each of 0.1 M CH3COOH–0.5 M NaCl (pH 4.0), binding buffer, and
PBS. Sera from 18 individuals from PNG were diluted to 1/50 in PBS, and 2 ml
of each batch was bound to 350 ml of affinity column for 16 h at 4°C. Individual
resins were poured into columns at 4°C (nonbound fractions were retained) and
washed with 5 ml each of PBS, PBS–0.5 M total NaCl, and PBS again. Elution
was at room temperature with 0.1 M glycine (pH 2.5) or 3 M MgCl2. Eluted
antibody solutions were immediately neutralized with 2 M Tris, dialyzed at 4°C
for 16 h in PBS, and concentrated in Centricon 10 microconcentration tubes
(Amicon, Beverly, Mass.).
Affinity purification was evaluated by performing standard and low-affinity
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Western blot experiments on P. falciparum clone 3D7 antigen extracts and on the
recombinant protein used for purification. The eluted antibody was used either
at an appropriate dilution without additions or after preincubation for 2 h at 4°C
with either 2 mg of the recombinant protein used for purification or CNBr-
Sepharose 4B preblocked with glycine. The conditions for low-affinity immuno-
blotting are described in reference 38.
Data analysis. Statistical analysis was performed with Epi Info version 6 to test
by analysis of variance if there existed a significant difference in the ages of
individuals with a certain discrete antibody level. The same test was used to
analyze the ages of individuals when parasitemia was categorized. If age distri-
bution was nonnormal, significance was tested by Kruskal-Wallis one-way anal-
ysis of variance. For these two tests, the resultant P value was multiplied by the
number of tests performed, an application of the Bonferroni correction to avoid
spurious values of P. The Wilcoxon rank sum two-sample test was used on
contiguous sets of mean antibody levels. Spearman nonlinear correlation analy-
ses were performed on sets of continuous data on antibody response to an
antigen versus that to a second antigen or on age and level of parasitemia of the
donor.
RESULTS
Antibody correlations with age. Immunoblotting and
ELISAs were performed with the sera of 100 individuals from
PNG against 11 recombinant and parasite-derived antigens. As
an example, Fig. 1 summarizes the antibody responses of the
100 PNG sera to parasite-derived RAP-1 by immunoblotting.
Also shown are the responses to total P. falciparum clone 3D7
schizont antigen and parasitemia. For both P. falciparum
RAP-1 (Fig. 1) and P. falciparum RAP-2, the proportion of
individuals with antibody to an antigen increased with age. In
the age group of individuals over 30 years old, 19 of 22 indi-
viduals had antibodies to P. falciparum RAP-1 by immunoblot
analysis and 18 of 22 had antibodies to P. falciparum RAP-2.
Two of the three individuals in this age group who had
FIG. 1. Antibody responses of the sera of 100 individuals from PNG. Shown are antibody responses to parasite-derived RAP-1 compared to total amounts of
schizont antigen, as measured by immunoblot analysis. The derivation of antibody units for the immunoblots (IB) and parasitemia are described in the text. Pf3D7,
P. falciparum clone 3D7; PfRAP-1, P. falciparum RAP-1.
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no detectable antibodies to P. falciparum RAP-1 also had no
detectable antibodies to P. falciparum RAP-2, and the third
individual had a weak reaction to P. falciparum RAP-2.
Establishment of the positive cutoff point as the mean plus 2
standard deviations of the scores of responses from the sera
from 26 nonexposed individuals from Brisbane was not possi-
ble with the rRAP-1 immunoblots. Twenty-four of 26 of the
Brisbane individuals were positive to rRAP-1 at a dilution of
1/400, with a mean scored signal strength of 2.2, giving a back-
ground signal cutoff of 5.3. This was 8.5-fold the background
level of any other antigen. Consequently, immunoblot data for
rRAP-1 was analyzed without the background signal being
removed.
The proportion of individuals with antibody to an antigen
increased with age for all antigens. To determine if this rela-
tion between age and antibody was significant, Spearman cor-
relation analyses were performed on the sets of continuous
data on antibody response to an antigen versus the age of the
donor. Spearman correlation analyses were used, as the data
distribution was nonnormal for both age and antibody re-
sponses (e.g., the mean age was 17.9 years, the median age was
13.0 years, and for antibodies to antigens rRAP-1 and rRAP-2
by ELISA, mean antibody units were 573.6 and 160.3, respec-
tively, compared to median antibody units of 35.3 and 0). For
Spearman correlation analyses, the greater the correlation co-
efficient (rs), the higher the correlation between age and anti-
body reactivity. Antibody levels to all antigens positively cor-
related with age for both ELISA and immunoblot data (all P
values were ,0.002, except with antigen rMSA2, where P val-
ues were ,0.02) (Fig. 2).
The strength of an antibody response to antigen rMSA2 was
very high even in the youngest age group. Hence, the response
had the lowest correlation coefficient (rs 5 0.25) and the lowest
P value, and so its correlation with age was further analyzed by
testing if there existed a significant difference in the ages of
individuals with certain discrete antibody levels, that is, to see
if older individuals had statistically higher antibody titers to
rMSA2. The median ages of individuals with immunoblot sig-
nal scores of 0 to 6 against rMSA2 were not significantly dif-
ferent (P 5 1.0 by analysis of variance). Nor were the median
ages of individuals with immunoblot signal scores of 0 to 6
significantly different for antigens P. falciparum MSA2 (P 5
0.28) and rMSP1 (P 5 0.56). However, a similar analysis of
immunoblot data for all other antigens did find a significant
difference between the median ages of individuals with a par-
ticular immunoblot antibody response score of 0 to 6 (all P
values were ,0.05).
The correlations described above between the titer of anti-
body to an antigen and age may reflect an increase in the
number of individuals with antibodies to that antigen with age
or increases in the level of antibody response to that antigen
with age. To distinguish between these two possibilities, me-
dian titers of antibodies to antigens for one age group (e.g., 0
to 5 years) were compared with those of a second age group
(e.g., .5 to 10 years). This was done both for all individuals
within an age group (where a statistical increase in a median
titers of antibody might reflect an increase in numbers of in-
dividuals with antibodies and/or an increase in the level of
antibody to that antigen) and for only those individuals within
the age group with detectable antibodies to the antigen (where
a statistical increase in the median titer of antibody to an
antigen reflected a real increase in the titer of antibody to that
antigen with age). Table 1 shows the results of Wilcoxon rank
sum pairwise tests comparing the median antibody responses
within age groups for all individuals with those for responders
alone (here the term responders refers to individuals with
antibodies at levels greater than the background for that anti-
gen). The primary difference in the responses to most antigens
in Table 1 is between the age groups 0 to 5 and .5 to 10 years.
This is due to an increase in the number of responders, as there
is no significant difference in the median levels of antibodies
among responders alone. Exceptions are the responses to total
P. falciparum clone 3D7 and antigen rMSP1, which show both
an increase in the number of responders and an increase in the
level of response. Conversely, the differences between the me-
dian responses in the older age groups reflect real increases in
the levels of antibodies to the antigens.
Median titers of antibodies to most antigens thus show a
steadily increasing trend among age groups, with a first signif-
icant increase between ages 0 to 5 and .5 to 10 years, due to
an increase in the number of responders, followed by a second
significant increase after 15 or 30 years of age, due to an
increase in the level of antibody per responder (summarized in
Fig. 3 for the immunoblot results for rRESA and P. falciparum
RAP-2).
Antibody correlations with parasitemia. The percentage of
parasitemic individuals decreased with increasing age, as did
the level of parasitemia (Fig. 1). When parasitemia was cate-
gorized into three groups (above the mean level of para-
sitemia, above no parasitemia, and no parasitemia), the me-
dian age of individuals within each group increased
significantly as parasitemia decreased (P 5 0.05 by Kruskal-
Wallis one-way analysis of variance).
As this was not a longitudinal survey, the effect of antibody
in the sera cannot be assessed for its potential effect on future
parasite growth. However, for both immunoblot and ELISA
data, antibodies to antigens rMSA2 and P. falciparum MSA2
were significantly higher in parasitemic individuals in the age
group 0 to 5 years than in nonparasitemic individuals (all P
values were ,0.02). This was also true for antigen rRESA in
the .10- to 15-year olds (P , 0.05). Spearman correlation
analyses also showed antigens rMSA2 (immunoblotting and
ELISA), P. falciparum MSA2 (immunoblotting), rRAP-2 (im-
munoblotting), and yMSP119 (immunoblotting) to correlate
positively with parasitemia (all P values were ,0.04).
FIG. 2. Correlation of age with antibody response for 100 sera of individuals
from PNG. Spearman correlation coefficients of donor age and antibody re-
sponse to an antigen are shown. Antibody was measured by immunoblot analysis
(IB) or ELISA. All correlation coefficients shown are significant (P , 0.002 for
all antigens except rMSA2, where P , 0.02). The greater the rs value, the higher
the correlation between age and reactivity. PfRAP-1 and -2, P. falciparum RAP-1
and -2, respectively; PfMSA2, P. falciparum MSA2; Pf3D7, P. falciparum clone
3D7.
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Antibody correlations between antigens. The associations
between antibody responses to one antigen and to the other
antigens were also analyzed by Spearman correlation analyses
(Fig. 4). The possible confounding effect that age may have had
on correlations was controlled for by repeating the correlations
within age groups (0 to 5, .5 to 10, .10 to 15, .15 to 30, and
.30 years). Those antigens with the highest rs value for the full
correlation are also those antigens which gave significant cor-
relation coefficients between antibody responses to different
antigens in each of the five age groups.
For the recombinant and total P. falciparum clone 3D7 an-
tigens, data from the two-assay system used (immunoblotting
and ELISA) correlate well. This is important in allowing com-
parisons between the results of the two assays, as when P.
falciparum RAP-1 and P. falciparum RAP-2 were used, since
there was sufficient antigen for immunoblotting only. Some
evidence of a correlation between the responses to RAP-1 and
RAP-2 was observed. However, the strongest correlations were
between recombinant and parasite-derived forms of the same
antigen, e.g., between rRAP-2 and P. falciparum RAP-2,
rMSA2 and P. falciparum MSA2, and rRAP-1 and P. falcipa-
rum RAP-1. The MSA2 antigens (rMSA2 and P. falciparum
MSA2) had the smallest rs values when they were compared
with other antigens, although they were still significant (Fig. 4).
Antibody responses to RAP-1 and RAP-2 in defined-infec-
tion sera. Antisera from two naive individuals infected with P.
falciparum sporozoites of the 3D7 clone were screened for
anti-rRAP-1 and -2 antibodies by ELISA and immunoblot
analysis. Figure 5 shows the immunoblots with sera at a 1/200
dilution. Volunteer 1 had IgM antibodies that recognized
rRAP-1 18 days after inoculation with sporozoites, coinciding
with the first IgM response to P. falciparum clone 3D7 antigen
extracts. Volunteer 2 (who had a lower parasitemia) showed
the same pattern in the next serum sample (21 days postinocu-
lation). In contrast to the IgM response, IgG responses to
TABLE 1. Significant Wilcoxon rank sum pairwise test P values on median titers of antibodies in the sera of donors grouped by agea
Test Antigen
No. of responders
to indicated antigen/total
no. of individuals in
age group (yr):
Pn Pm
No. of responders
to indicated antigen/total
no. of individuals in
age group (yr):
Pn Pm
No. of responders
to indicated antigen/total
no. of individuals in
age group (yr):
Pn Pm
0–5 .5–10 .10–15 .15–30 .15–30 .30
Immunoblot
analysis
rRAP-1 — — — — 19/19 19/19 0.04 0.04 — — — —
rRAP-2 — — — — — — — — 7/19 15/22 0.10 1.0
P. falciparum
RAP-2
5/21 11/19 0.04 0.10 — — — — 11/19 18/22 0.10 1.0
rMSA2 16/21 19/19 0.02 0.20 — — — — — — — —
P. falciparum
MSA2
14/21 18/19 0.01 0.10 — — — — — — — —
P. falciparum
clone 3D7
17/21 19/19 0.0002 0.0002 — — — — — — — —
rRESA 10/21 16/19 0.02 0.10 — — — — 15/19 22/22 0.0002 0.02
rMSP1 9/21 10/19 0.20 0.02 — — — — 11/19 16/22 0.04 0.02
ELISA rRAP-1 — — — — 16/19 18/19 0.02 0.04 18/19 19/22 0.10 0.01
rRAP-2 — — — — — — — — 13/19 17/22 0.10 0.02
rMSA2 16/21 19/19 0.10 1.0 18/19 19/19 0.02 0.02 — — — —
rRESA 18/21 19/19 0.20 1.0 — — — — 19/19 22/22 0.001 0.001
rMSP1 14/21 17/19 0.10 1.0 — — — — 17/19 22/22 0.04 0.10
P. falciparum
clone 3D7
20/21 19/19 0.04 0.10 19/19 19/19 0.04 0.04 — — — —
a Shown are the results of comparing the median titer of antibody to an antigen from an age group (e.g., 0 to 5 years) with that of the next oldest age group (e.g.,
.5 to 10 years) to determine if there is a significant difference between the two by the Wilcoxon rank sum pairwise test. Probabilities are shown both for comparisons
of the median titers of antibodies in sera from all individuals within an age group (Pn) and for comparisons of the median titers of antibodies in sera from only those
individuals with a titer above background (Pm) (m signifies the number of responders to an antigen in an age group). —, no significance exists for this comparison (some
nonsignificant results are shown when the results from tests performed with ELISA data disagree with those performed with the immunoblot data).
FIG. 3. Median titers of antibodies within an age group to the antigens
rRESA and P. falciparum RAP-2 (PfRAP-2) determined by immunoblot analy-
sis. Probability values from Wilcoxon rank sum pairwise tests between median
titers of adjacent age groups (e.g., 0 to 5 years with .5 to 10 years) are indicated.
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rRAP-1 preexisted in both samples. Both sera showed only
poor activity against rRAP-2 (IgM or IgG) at this dilution.
The anti-rRAP-1 IgG response on day 52 was titrated by
ELISA and compared to responses in positive (immune sera
from PNG) and negative (sera from Brisbane) pools. The
volunteers’ sera had anti-rRAP-1 IgG titers of 1/2,056 and
1/855 by ELISA, compared to titers of 1/2,529 for the positive
pool from immune donors from PNG and 1/40 for the negative
pool.
These two volunteers were subjected to a repeated asexual
blood stage infection with the same parasite line after a year.
Figure 6 summarizes the immunoblot and ELISA analyses of
the trial sera from volunteer 1 after subjection to several an-
tigens at a 1/400 dilution (i.e., a dilution equivalent to that used
in the analyses of PNG sera). The results with sera from vol-
unteer 2 follow similar trends (data not shown). The second
infection strongly boosted the antibody response, such that by
immunoblotting, the peak titers reached after two controlled
infections were equal to or in excess of the mean levels of
antibodies in sera of individuals over 30 years old from PNG
after exposure to rRAP-1 and P. falciparum RAP-1, rRAP-2
and P. falciparum RAP-2, rMSA2 and P. falciparum MSA2,
and rMSP1 and yMSP119.
Antibody specificity. Sera showing various types of anti-
rRAP-1 and -P. falciparum RAP-1 responses were purified on
rRAP-1 affinity columns. As a control, the same procedure was
followed for affinity purification of sera on rRESA columns.
Examples are shown in Fig. 7.
From five sera positive for rRESA, antibodies affinity puri-
fied on rRESA columns gave a P. falciparum recognition pat-
tern identical to that of the rRESA control sera and recognized
no other bands and the recognition was blocked by preincu-
bating the sera with soluble rRESA antigen. Three negative
control sera (PNG sera negative for rRESA but positive for
other P. falciparum antigens) purified the same way did not
recognize RESA or rRESA.
In contrast to the rRESA results, sera purified on rRAP-1
columns had antibodies with diverse reactivities to P. falcipa-
rum antigens. This was the case whether the immunoblotting
was performed under the low-affinity or more stringent stan-
dard immunoblot conditions. In only 4 of 10 cases where the
purified sera gave multiple antigen recognition could any re-
activity to P. falciparum RAP-1 be detected (confirmed by
MoAbs to P. falciparum RAP-1). The relative strengths of the
immunoblot signals to rRAP-1 and P. falciparum RAP-1 in the
prepurification sera did not seem to have any influence over
the reactivity pattern of the purified antibodies. Preincubation
of the affinity-purified antibodies with soluble rRAP-1 re-
moved all reactivity to rRAP-1 and PfRAP-1 by immunoblot
analysis but not to the other multiple P. falciparum antigens.
DISCUSSION
Antibody reactivities to rRAP-1 and rRAP-2 were markedly
distinct. rRAP-1 was strongly recognized, but rRAP-2 was
poorly recognized. This was not due to the inappropriateness
of the rRAP-2 molecule, as the same pattern was obtained with
the native forms of these molecules. However, the total num-
ber of responders among the 100 PNG sera was high, reaching
86% (RAP-1) and 82% (RAP-2) by immunoblot analysis in the
age group of individuals over 30 years. Some evidence for
correlation between the responses to these two molecules was
observed (Fig. 4) and may reflect the ability of antibodies
FIG. 4. Comparison of antibody responses to different antigens in the sera of 100 individuals from PNG. Spearman correlation coefficients of an antibody response
to one antigen with that to another are shown. All correlation coefficients shown are significant (P , 0.0002 for rs values of $0.5; P , 0.01 for rs values of $0.25). A
white 1 indicates that the correlation always remains significant when the regression is performed separately within age groups (0 to 5, .5 to 10, .10 to 15, .15 to
30, and .30 years), i.e., there are five significant values of rs. IB, immunoblot analysis; PfRAP-1 and -2, P. falciparum RAP-1 and -2, respectively; PfMSA2, P. falciparum
MSA2; Pf3D7, P. falciparum clone 3D7.
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raised against one of these antigens to cross-react with the
second (37, 38).
Figure 4 also shows important correlations between para-
site-derived and recombinant antigens (rRAP-1 and P. falcipa-
rum RAP-1, rRAP-2 and P. falciparum RAP-2, and rMSA2
and P. falciparum MSA2). As both the recombinant and par-
asite-derived molecules were denatured, a subset of conforma-
tionally dependent antibodies may not recognize either. How-
ever, the correlation between antibody recognition of parasite-
derived and recombinant material is encouraging for vaccine
development, as linear epitopes are shared between the dena-
tured recombinant and parasite-derived proteins. This is an
important finding for RAP-1 and RAP-2, for while immuniza-
tion with SDS-denatured P. falciparum RAP-1 and -2 gave
protection to monkeys from P. falciparum (28), no other com-
parable data exist on the possibilities of human immune re-
sponses to the recombinant proteins as immunogens.
The data presented here on multiple recombinant and par-
asite-derived forms of five asexual malarial antigens (and total
schizont antigen) are consistent with observations made in
previous studies on particular antigens (1–3, 13, 24, 30, 34, 35,
42). In those studies, adults were found to have significantly
higher levels of antibody to MSP1 than children and infected
children were found to have significantly more antibodies than
noninfected children (13, 42). Antibody response to MSP1 is
short-lived, with children losing antibodies faster than do
adults (24, 35). Similar distributions of antibody and para-
sitemia among age groups hold for RESA and MSA2, with a
higher antibody response at the beginning of the transmission
season (more likely in adults) being predictive of a decrease in
the incidence of clinical malaria (1, 2, 30). A similar protective
correlation of antibodies against regions of MSP1 was also
found in children (3).
We found, as have others (1, 2), that peak levels of antibod-
ies do not arise until an individual is over 30 years old. How-
ever, antibody levels after one infection in healthy adults can
approach these peak levels for antigen rRAP-1, but this anti-
body appears to be short-lived. A second infection strongly
boosts this response, such that in experimental infections of
two volunteers with P. falciparum, the peak titers reached after
two controlled infections were equal to or in excess of the
mean levels of antibodies in the age group of individuals over
30 years from PNG for rRAP-1 and P. falciparum RAP-1,
rRAP-2 and P. falciparum RAP-2, rMSA2 and P. falciparum
MSA2, and rMSP1 and yMSP119, and clear evidence of boost-
ing of antibody response is evident for all antigens (Fig. 6).
This pattern is apparently reflected in the boosting effect on
antibody levels of a concurrent parasitemia which is seen in the
age group 0 to 5 years in the PNG sera (13). Since this boosting
is not visible in older age groups, repeated exposure to malaria
may lead to a persistence of antibody rather than simply raising
levels of antibodies. An enhancement of antibody persistence
to multiple antigens which lasts until the next infection (in
areas of perennial transmission) or until the start of the next
transmission season may allow better control of infection and
hence lower morbidity (1).
Antibody responses to the full-length MSA2 antigens
(rMSA2 and P. falciparum MSA2) had the lowest rs values
when they were compared with antibody responses to other
antigens, although they were still significant. Antigens rMSA2
and P. falciparum MSA2 elicited the highest antibody re-
sponses in individuals from 0 to 30 years of age (after re-
sponses to total P. falciparum clone 3D7 schizont antigen),
while rNC elicited the lowest. The response to antigen rMSA2
showed only a weak correlation with age, and the mean titers
of antibodies to antigens rMSA2 and P. falciparum MSA2 were
not significantly different between age groups. In addition,
antigens rMSA2 (by immunoblotting and ELISA) and P. fal-
ciparum MSA2 (by immunoblotting) correlated positively with
parasitemia. Thus, rather than reflecting total malarial expo-
sure (via age), high levels of antibodies to full-length MSA2 are
equally likely in all age groups and may reflect exposure to the
3D7 allele. Conversely, although the number of responders
was small (13 of 100), the response to rNC (i.e., the conserved
regions of MSA2) had higher correlations with responses to
the other antigens and reflects total malarial exposure.
The response to rRAP-1 had three unusual aspects: a high
reactivity was found in nonexposed individuals, the strengths of
signals to rRAP-1 correlated with those to P. falciparum
RAP-1 but were in general stronger, and an increase in the
level of IgG to rRAP-1 was visible in naive volunteers 5 days
following inoculation with sporozoites. To investigate these
aspects of the response to rRAP-1, antibodies from PNG sera
were purified on rRAP-1 or rRESA affinity columns.
Antibody purified on rRESA columns reacts specifically with
P. falciparum extracts in a pattern characteristic of the control
antibody against this molecule. Preincubation of the extracted
antibodies with rRESA in a soluble form removes this reactiv-
ity to P. falciparum.
However, for antibodies affinity purified on rRAP-1, we
found strong evidence that the purified antibodies recognize
specific antigens other than P. falciparum RAP-1, i.e., prein-
cubation of the extracted antibodies with soluble rRAP-1 re-
moved reactivity to P. falciparum RAP-1 but not to other P.
FIG. 5. First infection antibody responses to P. falciparum. Shown are IgG
and IgM responses to rRAP-1, rRAP-2, and total P. falciparum clone 3D7
schizont antigen in an experimental sporozoite infection of two naive volunteers
infected with P. falciparum. Lanes a show IgM responses, and lanes b show IgG
responses for the samples at the indicated days postinoculation. Lanes (2) a and
b show the reactivity of the secondary antibody alone.
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falciparum antigens recognized. Such cross-reactivity can ex-
plain the high reactivity seen in unexposed Brisbane sera in this
study and the high background seen in two previous studies
(18, 22). It also helps to explain the early boosting of IgG
reactivity to rRAP-1 observed in the day-5-postinoculation
sera of the two volunteers. The timing of the boosting is prob-
ably too coincidental to be due to unrelated causes and may
have arisen due to antigens on circulating sporozoites. Thus,
the antigenicity of P. falciparum RAP-1 during natural infec-
tion with P. falciparum may have been overestimated in previ-
ous studies (18, 22) when only forms of rRAP-1 were used to
estimate anti-P. falciparum RAP-1 antibodies.
However, sera from an area of PNG where malaria is en-
demic demonstrate a widespread recognition of RAP-1 and
RAP-2. Although one or two infections with malaria can gen-
erate a humoral response of similar magnitude in healthy
adults, persistence of antibodies appears to be generated in
response to the total exposure to malaria of the host.
FIG. 6. IgG responses to multiple antigens in one volunteer over the course of two infections with P. falciparum. Antibodies were measured by immunoblot analysis
and ELISA. Arrows indicate infection times. For RAP-1, RAP-2, MSA2, and total P. falciparum clone 3D7 (Pf3D7), shaded symbols and dashed lines refer to
parasite-derived forms and filled symbols and lines refer to recombinant (r) forms. PfMSA2, P. falciparum MSA2; PfRAP-1 and -2, P. falciparum RAP-1 and -2,
respectively.
2336 STOWERS ET AL. INFECT. IMMUN.
 o
n
 February 6, 2017 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
ACKNOWLEDGMENTS
We express our gratitude to Patricia Graves for her assistance in
locating the original PNG serum collection data files.
This study was funded by the National Health and Medical Research
Council of Australia and the Australian Malaria Vaccine Joint Ven-
ture.
REFERENCES
1. Al-Yaman, F., B. Genton, R. Anders, J. Teraika, M. Ginny, S. Mellor, and
M. P. Alpers. 1995. Assessment of the role of the humoral response to
Plasmodium falciparum MSA2 compared to RESA and SPf66 in protecting
Papua New Guinean children from clinical malaria. Parasite Immunol. 17:
493–501.
2. Al-Yaman, F., B. Genton, M. Falk, R. Anders, D. Lewis, J. Hii, H.-P. Beck,
and M. P. Alpers. 1995. Humoral response to Plasmodium falciparum ring-
infected erythrocyte surface antigen in a highly endemic area of Papua New
Guinea. Am. J. Trop. Med. Hyg. 52:66–71.
3. Al-Yaman, F., B. Genton, K. J. Kramer, S. P. Chang, G. S. Hui, M. Baisor,
and M. P. Alpers. 1996. Assessment of the role of naturally acquired anti-
body levels to Plasmodium falciparum merozoite surface protein-1 in pro-
tecting Papua New Guinean children from malaria morbidity. Am. J. Trop.
Med. Hyg. 54:443–448.
4. Brown, H. J., and R. L. Coppel. 1991. Primary structure of a Plasmodium
falciparum rhoptry antigen. Mol. Biochem. Parasitol. 49:99–110.
5. Bushell, G. R., L. T. Ingram, C. A. Fardoulys, and J. A. Cooper. 1988. An
antigenic complex in the rhoptries of Plasmodium falciparum. Mol. Biochem.
Parasitol. 28:105–112.
6. Cattani, J. A., J. L. Tulloch, H. Vrbova, D. Jolley, F. D. Gibson, J. S. Moir,
P. F. Heywood, M. P. Alpers, A. Stevenson, and R. Clancy. 1986. The
epidemiology of malaria in a population surrounding Madang, Papua New
Guinea. Am. J. Trop. Med. Hyg. 35:3–15.
7. Cheng, Q., G. Lawrence, C. Reed, A. Stowers, L. Ranford-Cartwright, A.
Creasey, R. Carter, and A. Saul. Measurement of Plasmodium falciparum
growth rate in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg., in
press.
8. Clark, J. T., R. Anand, T. Akoglu, and J. S. McBride. 1987. Identification and
characterisation of proteins associated with the rhoptry organelles of Plas-
modium falciparum merozoites. Parasitology 18:183–195.
9. Cooper, J. A., L. T. Cooper, and A. J. Saul. 1992. Mapping of the region
predominantly recognised by antibodies to the Plasmodium falciparum mer-
ozoite surface antigen MSA 1. Mol. Biochem. Parasitol. 51:301–312.
10. Cooper, J. A., L. T. Ingram, G. R. Bushell, C. A. Fardoulys, D. Stenzel, L.
Schofield, and A. Saul. 1988. The 140/130/105 kilodalton protein complex in
the rhoptries of Plasmodium falciparum consists of discrete polypeptides.
Mol. Biochem. Parasitol. 29:251–260.
11. Coppel, R. L., A. F. Cowman, R. F. Anders, A. C. Bianco, R. B. Saint, K. R.
Lingelbach, D. J. Kemp, and G. V. Brown. 1984. Immune sera recognise an
erythrocyte Plasmodium falciparum antigen composed of repeated amino
acid sequences. Nature 310:789–792.
12. Epping, R. J., S. D. Goldstone, L. T. Ingram, J. A. Upcroft, R. Ramasamy,
J. A. Cooper, G. R. Bushell, and H. M. Geysen. 1988. An epitope recognised
by inhibitory monoclonal antibodies that react with a 51 kilodalton merozo-
ite surface antigen in Plasmodium falciparum. Mol. Biochem. Parasitol. 28:
1–10.
13. Fru¨h, K., O. Doumbo, H. M. Muller, O. Koita, J. McBride, A. Crisanti, Y.
Toure´, and H. Bujard. 1991. Human antibody response to the major mero-
zoite surface antigen of Plasmodium falciparum is strain specific and short-
lived. Infect. Immun. 59:1319–1324.
14. Gentz, R., U. Certa, B. Takacs, H. Matile, H. Dobeli, J. R. L. Pink, M.
MacKay, N. Bone, and J. G. Scaife. 1988. Major surface antigen p190 of
Plasmodium falciparum: detection of non-variable epitopes present in a
variety of plasmodia isolates and their high yield expression in E. coli. EMBO
J. 7:225–230.
FIG. 7. Affinity purification of antibodies to RESA by antigen rRESA (A) and to P. falciparum RAP-1 (PfRAP-1) by antigen rRAP-1 (B). The sera were
immunoblotted against recombinant antigens in the bottom panels (rRESA [1505H], rMSA2 [1624], and rRAP-1) and Triton X-100 detergent extracts of 3D7 schizont
antigen in the top panels, under nonreducing conditions. By affinity purification, the serum in gel i was negative to the purification antigen and sera in gels ii, iii, iv,
and v were positive to the indicated antigens. Lanes: c, control antibody (7H8/50 for rRAP-1 and mouse anti-rRESA for rRESA); 1, total antibodies prior to purification;
2, antibodies that did not bind to the affinity column; 3, antibodies that eluted from the column; 4, sample in lane 3 preincubated with affinity purification recombinant
protein; 5, sample in lane 3 preincubated with glycine-blocked CNBr-Sepharose 4B. PfRESA, P. falciparum RESA.
VOL. 65, 1997 HUMORAL RESPONSE TO RAP-1 AND RAP-2 2337
 o
n
 February 6, 2017 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
15. Harnyuttanakorn, P., J. S. McBride, S. Donachie, H.-G. Heidrich, and R. G.
Ridley. 1992. Inhibitory monoclonal antibodies recognise epitopes adjacent
to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falcipa-
rum. Mol. Biochem. Parasitol. 55:177–186.
16. Holder, A. A., M. J. Lockyer, K. G. Odink, J. S. Sandhu, and V. Riveros-
Moreno. 1985. Primary structure of the precursor to the three major surface
antigens of Plasmodium falciparum merozoites. Nature 317:270–273.
17. Howard, R. 1992. The sequence of the p82 rhoptry protein is highly con-
served between two Plasmodium falciparum isolates. Mol. Biochem. Parasi-
tol. 51:327–330.
18. Howard, R. F., J. B. Jensen, and H. L. Franklin. 1993. Reactivity profile of
human anti-82-kilodalton rhoptry protein antibodies generated during nat-
ural infection with Plasmodium falciparum. Infect. Immun. 61:2960–2965.
19. Howard, R. F., and C. Peterson. 1996. Limited RAP-1 sequence diversity in
field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 77:95–98.
20. Howard, R. F., H. A. Stanley, G. H. Campbell, and R. T. Reese. 1984.
Proteins responsible for a punctate fluorescence pattern in Plasmodium
falciparum merozoites. Am. J. Trop. Med. Hyg. 33:1055–1059.
21. Howard, R. J., and B. L. Pasloske. 1993. Target antigens for asexual malaria
vaccine development. Parasitol. Today 9:369–372.
22. Jakobsen, P. H., L. Hviid, T. G. Theander, E. A. Afare, R. G. Ridley, P. M. H.
Heegaard, D. Stuber, K. Dalsgaard, and F. K. Nkrumah. 1993. Specific
T-cell recognition of the merozoite proteins rhoptry-associated protein 1 and
erythrocyte-binding antigen 1 of P. falciparum. Infect. Immun. 61:268–273.
23. Kaslow, D. C., G. Hui, and S. Kumar. 1994. Expression and antigenicity of
Plasmodium falciparum major merozoite surface protein (MSP1(19)) vari-
ants secreted from Saccharomyces cerevisiae. Mol. Biochem. Parasitol. 63:
283–289.
24. Mu¨ller, H. M., K. Fru¨h, A. von-Brunn, F. Esposito, S. Lombardi, A. Crisanti,
and H. Bujard. 1989. Development of the human immune response against
the major surface protein (gp190) of Plasmodium falciparum. Infect. Immun.
57:3765–3769.
25. Perrin, L. H., B. Merkli, M. S. Gabra, J. W. Stocker, C. Chizzolini, and R.
Richie. 1985. Immunization with a Plasmodium falciparum merozoite surface
antigen induces a partial immunity in monkeys. J. Clin. Invest. 75:1718–1721.
26. Perrin, L. H., E. Ramirez, P. H. Lambert, and P. A. Miescher. 1981. Inhi-
bition of P. falciparum growth in human erythrocytes by monoclonal anti-
bodies. Nature 289:301–303.
26a.Prescott, N. Unpublished data.
27. Ridley, R. G., H. Lahm, B. Takacs, and J. G. Scaife. 1991. Genetic and
structural relationships between components of a protective rhoptry antigen
complex from Plasmodium falciparum. Mol. Biochem. Parasitol. 47:245–246.
28. Ridley, R. G., B. Takacs, H. Etlinger, and J. G. Scaife. 1990. A rhoptry
antigen of Plasmodium falciparum is protective in Saimiri monkeys. Parasi-
tology 101:187–192.
29. Ridley, R. G., B. Takacs, H. Lahm, C. J. Delves, M. Goman, U. Certa, H.
Matile, G. R. Woollett, and J. G. Scaife. 1990. Characterisation and sequence
of a protective rhoptry antigen from Plasmodium falciparum. Mol. Biochem.
Parasitol. 41:125–134.
30. Rooth, I., H. Perlmann, and A. Bjorkman. 1991. Plasmodium falciparum
reinfection in children from a holoendemic area in relation to seroreactivi-
ties against oligopeptides from different malarial antigens. Am. J. Trop.
Med. Hyg. 45:309–318.
30a.Saul, A., et al. Unpublished data.
31. Saul, A., J. Cooper, D. Hauquitz, D. Irving, Q. Cheng, A. Stowers, and T.
Limpaiboon. 1992. The 42-kilodalton rhoptry-associated protein of Plasmo-
dium falciparum. Mol. Biochem. Parasitol. 50:139–150.
32. Saul, A., P. Myler, T. Elliot, and C. Kidson. 1982. Purification of mature
schizonts of Plasmodium falciparum on colloidal silica gradients. Bull.
W. H. O. 60:755–759.
33. Schofield, L., G. R. Bushell, J. A. Cooper, A. J. Saul, J. A. Upcroft, and C.
Kidson. 1986. A rhoptry antigen of Plasmodium falciparum contains con-
served and variable epitopes recognised by inhibitory monoclonal antibodies.
Mol. Biochem. Parasitol. 18:183–195.
34. Shi, Y. P., U. Sayed, S. H. Qari, J. M. Roberts, V. Udhayakumar, A. J. Oloo,
W. A. Hawley, D. C. Kaslow, B. L. Nahlen, and A. A. Lal. 1996. Natural
immune response to the C-terminal 19-kilodalton domain of Plasmodium
falciparum merozoite surface protein 1. Infect. Immun. 64:2716–2723.
35. Sinigaglia, F., B. Takacs, H. Jacot, H. Matile, J. R. Pink, A. Crisanti, and H.
Bujard. 1988. Nonpolymorphic regions of p190, a protein of the Plasmodium
falciparum erythrocytic stage, contain both T and B cell epitopes. J. Immu-
nol. 140:3568–3572.
36. Smythe, J. A., R. L. Coppel, G. V. Brown, R. Ramasamy, D. J. Kemp, and
R. F. Anders. 1988. Identification of two integral membrane proteins of
Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 85:5195–5199.
37. Stowers, A., N. Prescott, J. Cooper, B. Takacs, D. Stueber, P. Kennedy, and
A. Saul. 1995. Immunogenicity of recombinant Plasmodium falciparum
rhoptry associated proteins 1 and 2. Parasite Immunol. 17:631–642.
38. Stowers, A. W., J. A. Cooper, T. Erhhardt, and A. Saul. 1996. A peptide
derived from a B cell epitope of Plasmodium falciparum rhoptry associated
protein 2 specifically raises antibodies to rhoptry associated protein 1. Mol.
Biochem. Parasitol. 82:167–180.
39. Stowers, A. W., K. J. Spring, and A. Saul. 1995. Preparative scale purification
of recombinant proteins to clinical grade by isotachophoresis. Bio/Technol-
ogy 13:1498–1503.
40. Stu¨rchler, D., R. Berger, C. Rudin, M. Just, A. Saul, C. Rzepczyk, G. Brown,
R. Anders, R. Coppel, G. Woodrow, D. Pye, F. Sorennson, D. Gillessen, H.
Matile, and R. Reber-Liske. 1995. Safety, immunogenicity and pilot efficacy
of Plasmodium falciparum sporozoite and asexual blood-stage combination
vaccine in Swiss adults. Am. J. Trop. Med. Hyg. 53:423–432.
41. Tanabe, K., M. MacKay, M. Gorman, and J. Scaife. 1987. Allelic dimor-
phism in a surface antigen gene of the malaria parasite Plasmodium falcipa-
rum. J. Mol. Biol. 195:273–278.
42. Tolle, R., K. Fru¨h, O. Doumbo, O. Koita, M. N’Diaye, A. Fischer, K. Dietz,
and H. Bujard. 1993. A prospective study of the association between the
human humoral immune response to Plasmodium falciparum blood stage
antigen gp190 and control of malarial infections. Infect. Immun. 61:40–47.
43. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous
culture. Science 193:673–675.
44. Walliker, D., I. A. Quakyi, and T. E. Wellems. 1987. Genetic analysis of the
human malaria parasite Plasmodium falciparum. Science 236:1661–1666.
Editor: S. H. E. Kaufmann
2338 STOWERS ET AL. INFECT. IMMUN.
 o
n
 February 6, 2017 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
